Tyrer-Cuzick Test for Breast Cancer Risk Assessment

Breast cancer remains one of the most common cancers affecting women in Australia and worldwide. Early detection and personalised risk assessment are central to improving outcomes. One of the most clinically recognised tools for evaluating individual risk is the Tyrer-Cuzick model, also known as the IBIS Breast Cancer Risk Evaluation Tool.

This article explains how the Tyrer-Cuzick model works, what it measures, how to interpret your results, and how it fits within Australia's evolving approach to breast cancer screening. As with all health information, the guidance here is general in nature and does not replace advice from your treating doctor or specialist.

‍

‍

What Is the Tyrer-Cuzick Model?

The Tyrer-Cuzick model is a statistical tool designed to estimate a person's risk of developing invasive breast cancer, both over the next 10 years and across their lifetime (up to age 85). It was first published in 2004 and has been updated over time (most recently to Version 8 in 2017), incorporating new evidence about the genetic and hormonal factors that influence breast cancer risk.

What distinguishes the Tyrer-Cuzick model from simpler tools?

It's the breadth of data it draws on. Rather than focusing on one or two risk factors, it integrates personal medical history, detailed family history across multiple generations, hormonal and reproductive factors, and genetic information into a single, individualised risk estimate.

The tool is used in clinical settings across Australia, the UK, the US, and internationally, and is recognised by Cancer Australia as part of its familial risk assessment framework.

Important note on who this tool applies to: The Tyrer-Cuzick model was developed primarily using data from people assigned female at birth. People who are transgender or non-binary with breast tissue should discuss their individual risk profile with their GP or a specialist, as standard risk models may require clinical adaptation.

Why Personalised Risk Assessment Matters

Traditional breast cancer screening programmes use a "one size fits all" approach, offering mammograms at set ages regardless of individual risk.

While this has clear public health benefits, it doesn't account for the significant variation in risk between individuals.

Personalised risk assessment tools like the Tyrer-Cuzick model allow clinicians and patients to make more informed decisions: people at higher risk may benefit from earlier or more frequent screening, additional imaging (such as MRI), or preventive strategies; people at lower risk may be appropriately reassured.

This shift toward risk-stratified care is now a growing focus of breast health policy in Australia and internationally.

‍

‍

How Does the Tyrer-Cuzick Calculator Work?

The calculator requires detailed input about personal and family medical history.

By analysing this data, it produces two primary risk estimates for invasive breast cancer:

• 10-year risk: The probability of developing breast cancer in the next 10 years.
• Lifetime risk: The probability of developing breast cancer up to age 85.

These estimates guide decisions about screening frequency, imaging modality, referral to genetic counselling, and in some cases, preventive medications or specialist consultation.

Key Inputs

1. Personal Medical History

• Age: Risk of breast cancer increases with age, with most cases diagnosed in women over 50.
  ‍
• Body Mass Index (BMI): Higher BMI elevates risk, particularly in postmenopausal people, partly due to increased circulating oestrogen from fatty tissue.
  ‍
• Menstrual History: Early onset of menstruation and late menopause are associated with higher risk due to prolonged hormonal exposure.
  ‍
• Reproductive History: Age at first full-term pregnancy and number of pregnancies influence lifetime hormonal exposure.
  ‍
• Biopsy History: A history of atypical hyperplasia or lobular carcinoma in situ (LCIS) significantly raises breast cancer risk. Note: research has shown that the Tyrer-Cuzick model may overestimate risk in women with atypical hyperplasia specifically. See Limitations below.
  ‍
• Breast Density: Women with dense breast tissue face a higher risk of breast cancer. Density is assessed by mammogram and classified using the BI-RADS system (A to D, from almost entirely fatty to extremely dense).

2. Family History

• First-degree relatives: A history of breast or ovarian cancer in a mother, sister, or daughter significantly raises risk.
  ‍
• Extended family history: A key strength of the Tyrer-Cuzick model is that it looks beyond first-degree relatives to include second-degree and more distant relatives, and accounts for the age at which family members were diagnosed. These are factors that simpler models overlook.
  ‍
• Male breast cancer: Family history of male breast cancer is also incorporated, which can indicate hereditary risk patterns.

3. Hormonal Factors

• Hormone Replacement Therapy (HRT): Duration and type of HRT use are factored into the model. The relationship between HRT and breast cancer risk has evolved significantly in recent years and is discussed in more detail below.
  ‍
• Height: Height is included as a proxy for hormonal and developmental factors associated with cancer risk.

4. Genetic Factors

• BRCA1 and BRCA2: Known pathogenic variants in these genes greatly elevate lifetime breast cancer risk and are incorporated into the model's genetic risk calculations.
  ‍
• Other genes: Clinical awareness of additional moderate- to high-risk genes (such as PALB2, CHEK2, and ATM) is increasing, though these are not all currently incorporated into the Tyrer-Cuzick model. Women with variants in these genes should discuss their risk with a genetic counsellor.

‍

Interpreting the Results

Risk Categories

• Average Risk: Lifetime risk below 15%.
• Moderate Risk: Lifetime risk between 15% and 19%.
• High Risk: Lifetime risk above 20%.

These categories are used by clinicians to guide screening recommendations.

A high Tyrer-Cuzick score does not mean you will develop breast cancer.

It means your risk is elevated relative to the general population, and that additional monitoring or preventive discussion may be appropriate.

What to Do With Your Tyrer-Cuzick Score

Your Tyrer-Cuzick result should always be interpreted in consultation with your GP or a specialist, who will consider it alongside your full clinical picture.

General guidance includes:

• Average risk (below 15%): Standard BreastScreen Australia two-yearly mammography from age 50–74 (or from 40 if you prefer) is appropriate.
  ‍
• Moderate risk (15%–19%): Your GP may recommend earlier commencement of screening or more frequent mammography, and may refer you for further risk assessment.
  ‍
• High risk (20% and above): Enhanced surveillance is typically recommended, including annual mammography. Women with a lifetime risk above 30%, or a 10-year absolute risk above 5%, may be eligible for a Medicare-rebated breast MRI (Item 63464) if they are under 60 years of age. Referral to a breast specialist or genetic counselling service is strongly recommended.

Preventive options, including risk-reducing medications, exist and may be appropriate for some people at high risk. These are clinical decisions to be made with your healthcare team, not based on a risk score alone.

How the Tyrer-Cuzick Model Compares to Other Tools

The Tyrer-Cuzick model is one of several validated breast cancer risk tools used in clinical practice:

• Gail Model: Focuses on short-term (5-year) risk and is quick to use, but does not account for genetic mutations or detailed multi-generational family history.
  ‍
• CanRisk Tool: Uses the BOADICEA engine and incorporates genetic, familial, hormonal, and lifestyle factors. It is increasingly used in clinical genetics settings in Australia and the UK for women with complex risk profiles or known gene variants.
  ‍
• BCSC Model: Used primarily in the United States; incorporates breast density and is well-validated in large screening populations.

The Tyrer-Cuzick model is often preferred for its detailed multi-factorial approach, particularly its extended family history capture and inclusion of BRCA1/2.

No single model is universally superior, and the right tool depends on individual circumstances.

Breast Cancer Screening and Surveillance

Here are some common methods used to screen for and monitor breast cancer:

1. Mammography: Mammograms are X-ray images of the breast that can detect tumours too small to be felt. Regular mammograms are recommended for women over 40 or earlier for those at higher risk.
   ‍
2. Monthly Self-Examinations: Regular self-checks promote breast awareness and help you notice any changes early, such as lumps, thickening, or skin changes. While not a substitute for screening, they can support early detection.
   ‍
3. Breast MRI: Magnetic resonance imaging (MRI) of the breast uses magnetic fields and radio waves to create detailed images, often used for women at high risk or with dense breast tissue. Breast MRI may be a better cancer detection tool than mammography in younger women.
   ‍
4. Ultrasound: Breast ultrasound employs high-frequency sound waves to produce images of the breast, useful for evaluating abnormalities found during a mammogram or physical exam.
   ‍
5. Breast Cancer Risk Assessment: Tools like the Tyrer-Cuzick model estimate a woman’s risk of developing breast cancer based on individual risk factors, guiding decisions about screening and preventive measures.

The Tyrer-Cuzick risk assessment calculator can help identify if enhanced screening is needed.

Breast Density

Breast density refers to the proportion of glandular and connective tissue relative to fatty tissue as seen on a mammogram.

It is classified on a four-point BI-RADS scale: A (almost entirely fatty), B (scattered fibroglandular), C (heterogeneously dense), and D (extremely dense).

Dense breast tissue raises breast cancer risk in two ways: it is associated with a higher biological risk of cancer, and it can obscure tumours on mammograms, making early detection harder.

Women with heterogeneously or extremely dense breasts (categories C and D) have approximately 1.6 to 2 times the cancer risk of women with fatty breasts.

Important Policy Change: You Now Have the Right to Know Your Density

In a landmark policy update, BreastScreen Australia's 2024 Position Statement now recommends that all women screened through BreastScreen be informed in writing of their breast density following a screening mammogram. This is a significant shift from previous policy. Women are encouraged to discuss what their density result means for their screening choices with their GP or breast cancer specialist.

Implementation is rolling out across Australian states and territories, with some programs (including South Australia from 2023 and Victoria from 2024/2025) already notifying women routinely. If you have had a BreastScreen mammogram and were not informed of your breast density, you can ask your GP to request this information.

If you have dense breasts, supplemental screening options such as ultrasound or MRI are available outside the BreastScreen program through a GP referral. These are discussed with you in the context of your overall risk profile and personal circumstances.

Limitations of the Tyrer-Cuzick Model

The Tyrer-Cuzick model is a valuable clinical tool, but it has important limitations that should be understood:

• Data quality: The model's output is only as reliable as the information entered. Incomplete or inaccurate family history will affect accuracy.
  ‍
• Population specificity: The model was validated primarily in populations of European ancestry. It may be less accurate for women of other ethnic backgrounds due to differences in underlying risk factor prevalence and genetic architecture.
  ‍
• Atypical hyperplasia: Research has shown that the Tyrer-Cuzick model significantly overestimates breast cancer risk in women with atypical hyperplasia, and shows poor concordance between predicted and actual risk in this group. Women with this diagnosis should discuss risk assessment with a specialist rather than relying on the Tyrer-Cuzick score alone.
  ‍
• Lifestyle factors excluded: Diet, physical activity, alcohol consumption, and environmental exposures are not incorporated into the model, meaning the score does not capture the full picture of modifiable risk.
  ‍
• Evolving evidence: Risk factor relationships, particularly around HRT, continue to be refined as new data emerges. The model reflects evidence available at the time of its last update (Version 8, 2017) and may not fully incorporate the most recent findings.
  ‍
• Not a diagnostic tool: A high score does not mean you have or will develop breast cancer. It is one input into a broader clinical conversation.

‍

‍

Frequently Asked Questions

1. How do I interpret my Tyrer-Cuzick score?

‍The score represents your estimated probability of developing invasive breast cancer, either over the next 10 years or across your lifetime (to age 85). Below 15% is considered average risk, 15–19% is moderate, and 20% or above is high risk. Your GP can help you understand what your score means for your screening plan.

2. What is a normal or average Tyrer-Cuzick score?

‍A lifetime risk below 15% is considered average, meaning your risk is in line with the general population.

3. How do I get a Tyrer-Cuzick assessment in Australia?

‍The assessment is available through your GP, through specialist breast clinics, or through preventive health services like Everlab. Some clinics offer it as part of a broader health risk review. Online results should always be discussed with a clinician.

4. Can I get a breast MRI through Medicare?

‍Yes, in certain circumstances. Women under 60 with a lifetime risk greater than 30% or a 10-year absolute risk greater than 5% (assessed using a clinically validated tool such as Tyrer-Cuzick) may be eligible for a Medicare rebate for breast MRI under Item 63464. Speak to your GP about whether you qualify.

5. What happens after a high-risk result?

‍A high Tyrer-Cuzick score typically triggers a conversation with your GP about enhanced surveillance (e.g., annual mammography and/or MRI), referral to a familial cancer clinic or genetic counsellor, and discussion of preventive options. It does not require immediate action, but it does open the door to a more tailored approach to your breast health.

6. Does a high score mean I should have a mastectomy?

‍No. Preventive surgery is very rarely indicated and is a decision reserved for a small number of people with very high genetic risk (such as confirmed BRCA1/2 pathogenic variants), made jointly with a specialist team after thorough discussion. A risk score alone is never the basis for this decision.

7. What is a high-risk Gail score?

‍The Gail model uses a different calculation method. A 5-year risk of 1.67% or higher is often used as a threshold for clinical decision-making in some guidelines, particularly for women over 35 considering preventive medications.

Sources

1. IBIS Breast Cancer Risk Evaluation Tool – Official Tyrer-Cuzick Model Website - https://ibis.ikonopedia.com
2. Cancer Australia – Familial Risk Assessment FRA-BOC - https://healthinfonet.ecu.edu.au/key-resources/resources/33076/?title=Familial+Risk+Assessment+FRA+BOC&contenttypeid=1&contentid=33076_1
3. ‍National Cancer Institute – Breast Cancer Risk Assessment Tool (Gail Model) - https://bcrisktool.cancer.gov

Disclaimer: This article is for general health information purposes only. It does not constitute medical advice and does not replace a consultation with your treating GP, specialist, or genetic counsellor. Individual risk assessment and screening decisions should always be made in partnership with a qualified healthcare professional.